KaloBios Pharmaceuticals Inc Share Price Nasdaq
Equities
US48344T2096
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
04-12 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
03-08 | Final DIP Financing Approved for Humanigen, Inc. | CI |
Sales 2021 | 3.6 283.37 | Sales 2022 | 2.51 198.16 | Capitalization | 14.29M 1.13B |
---|---|---|---|---|---|
Net income 2021 | -237M -18.68B | Net income 2022 | -70M -5.52B | EV / Sales 2021 | 53,517,059 x |
Net cash position 2021 | 45.01M 3.55B | Net cash position 2022 | 10.16M 800M | EV / Sales 2022 | 1,644,636 x |
P/E ratio 2021 |
-0.92
x | P/E ratio 2022 |
-0.15
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.65% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 06/01/16 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 05/07/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 06/01/16 |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 05/07/20 |
Ronald Barliant
BRD | Director/Board Member | 78 | 06/01/16 |
1st Jan change | Capi. | |
---|---|---|
-1.26% | 89.46B | |
+2.76% | 40.74B | |
-9.06% | 33.03B | |
+55.32% | 24.68B | |
-16.61% | 15.12B | |
-9.14% | 12.81B | |
-12.11% | 11.79B | |
-43.61% | 11.64B | |
+7.79% | 8.9B |